The Griffin Institute’s scientific and research team provides high quality studies to propel research, through the most appropriate models, into the marketplace. The team recently performed three haemostasis studies supporting the research and development of a new product, TenaTac®, an innovative surgical haemostat. Below is a case study presented by Ben Nichols and Paul Hayes of Selentus Science Ltd that explains more about the Project.
Aim/Challenge Bleeding is a common problem during surgical procedures and haemostats in the form of resorbable sponges or gels are used as treatments. Haemostats also contain blood-derived clotting proteins to enhance their effect and to ensure they adhere to the wound, to prevent dislodgement and post-operative bleeding.
Solution Selentus embarked on a project to develop a haemostat without the use of blood-derived ingredients to reduce the risk to patients from blood derived contaminants. Selentus’ technology is based on a patented laser guided surface modification that greatly increases the adhesion of sponges to wounds. The new product, TenaTac®, was tested at The Griffin Institute. https://www.selentus.com/how-it-works
Benefit In addition to eliminating blood derived ingredients, trials at The Griffin Institute have demonstrated that TenaTac® is superior to the leading product with respect to controlling bleeding and adhesion to wounds.
Result The new product, TenaTac®, was recently approved in Europe as a Class III Medical Device and with a patent granted in the USA, UK and Japan and pending worldwide.
For more information contact j.hua@griffininstitute.org.uk and a.rosen@griffininstitute.org
